Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H38N |
| Molecular Weight | 304.5339 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCC[n+]1ccccc1
InChI
InChIKey=NEUSVAOJNUQRTM-UHFFFAOYSA-N
InChI=1S/C21H38N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21H,2-14,16,19H2,1H3/q+1
Cetylpyridinium (used in a form of chloride salt) is a cationic surface-active agent and has a broad antimicrobial spectrum, with rapid killing of gram-positive pathogens and yeast in particular. It is suggested that interaction with bacteria occurs by the disruption of membrane function, leakage of cytoplasmic material, and ultimately the collapse of the intra-cellular equilibrium. The drug is used under various trade names as an oral OTC hygiene product (mouthwash, dental kits, etc.) to control the dental plaque and to prevent the subsequent gingivitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Bacterial membrane |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | ANTISEPTIC (cetylpyridinium chloride) mouthwash Approved UseHelp to control plaque that leads to gingivitis. |
|||
| Curative | ANTISEPTIC (cetylpyridinium chloride) mouthwash Approved UseHelp to control plaque that leads to gingivitis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10 mg/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16477395/ |
6 μL single, topical dose: 6 μL route of administration: Topical experiment type: SINGLE co-administered: |
CETYLPYRIDINIUM unknown | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
127 mg × h/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16477395/ |
6 μL single, topical dose: 6 μL route of administration: Topical experiment type: SINGLE co-administered: |
CETYLPYRIDINIUM unknown | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The kinetics and thermodynamics of surfactants in solvent sublation. | 2001 Aug |
|
| Spectrophotometric determination of cetylpyridinium chloride in pharmaceutical products. | 2001 Aug |
|
| [Effect of antiseptic treatment of alveolar surgical wounds on bacterial growth on cotton suture threads]. | 2001 Jan-Mar |
|
| A multifactorial investigation of the ability of oral health care products (OHCPs) to alleviate oral malodour. | 2001 Jul |
|
| Passive immunization with milk produced from an immunized cow prevents oral recolonization by Streptococcus mutans. | 2001 Nov |
|
| Gene expression by human articular chondrocytes cultured in alginate beads. | 2001 Oct |
|
| Effect of antimicrobial mouthrinses on the in vitro adhesion of Candida albicans to human buccal epithelial cells. | 2001 Sep |
|
| Effect of different mouthrinses on morning breath. | 2001 Sep |
|
| Comparative evaluation of four decontamination protocols for the isolation of Mycobacterium avium subsp. paratuberculosis from milk. | 2001 Sep |
|
| Development and validation of a photometric titration method for the quantitation of sodium chondroitin sulfate (bovine) in Cosequin DS chewable tablet. | 2002 Apr 15 |
|
| Solubility, chemical and photochemical stability of curcumin in surfactant solutions. Studies of curcumin and curcuminoids, XXVIII. | 2002 Dec |
|
| Time-resolved fluorometric analysis of carbohydrates labeled with amino-aromatic compounds by reductive amination. | 2002 Jul |
|
| Interaction of cetylpyridine bromide with nucleic acids and determination of nucleic acids at nanogram levels based on the enhancement of resonance Rayleigh light scattering. | 2002 Jul |
|
| [Method for determining nitrogen-containing cationic surface-active agents using butyrylcholinesterase]. | 2002 Mar-Apr |
|
| Glycosaminoglycan blotting on nitrocellulose membranes treated with cetylpyridinium chloride after agarose-gel electrophoretic separation. | 2002 Sep |
|
| Differences in antimicrobial activity of four commercial 0.12% chlorhexidine mouthrinse formulations: an in vitro contact test and salivary bacterial counts study. | 2003 Apr |
|
| Comparative study on fluorescence enhancement and quenching of europium and terbium chelate anions in cationic micelles. | 2003 Jan 15 |
|
| Inactivation kinetics of mushroom tyrosinase by cetylpyridinium chloride. | 2003 Jul |
|
| Purification of sulfated fucoglucuronomannan lyase from bacterial strain of Fucobacter marina and study of appropriate conditions for its enzyme digestion. | 2003 Jul-Aug |
|
| Cooling towers--a potential environmental source of slow-growing mycobacterial species. | 2003 Mar-Apr |
|
| Evaluation of cetylpyridinium chloride for infection control in storage solution. | 2003 May |
|
| Direct and specific recognition of glycosaminoglycans by antibodies after their separation by agarose gel electrophoresis and blotting on cetylpyridinium chloride-treated nitrocellulose membranes. | 2003 May |
|
| [DNA complexes, formed on aqueous phase surfaces: new planar polymeric and composite nanostructures]. | 2003 Nov-Dec |
|
| Inhibition of orally produced volatile sulfur compounds by zinc, chlorhexidine or cetylpyridinium chloride--effect of concentration. | 2003 Oct |
|
| Quenching of fluorescence of 1-hydroxypyrene-3,6,8-trisulfonate (HPTS) by Cu2+, Co2+, Ni2+, I-, and cetylpyridinium (CP+) ions in water/AOT/heptane microemulsion. | 2004 Mar 1 |
Sample Use Guides
Rinse for 30 seconds with 20 ml (4 teaspoonsfuls) twice a day, do not swallow.
Route of Administration:
Dental
The panel of 24 laboratory strains including 18 oral bacteria, five nonoral bacterialspecies and the yeast Candida albicans was incubated with twofold serial dilutions of the 0.05% cetylpyridinium chloride mouthrinse for 48-72 h at 35 celsius degrees. For the agar dilution assays of cultivable plaque bacte-ria, the drug was added at a final concentration of 1%. MIC values were 1.5-3% for Aggregatibacter actinomycetemcomitans and Capnocytophaga gingivalis, 0.375% for Actinomyces meyeri, Moraxella catarrhalis, Campylobacter rectus, 0.187-0.375 % for Porphyromonas gingivalis, etc.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28394
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-ATC |
R02AA06
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-ATC |
D08AJ03
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-VATC |
QR02AA06
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-VATC |
QD09AA07
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-ATC |
D09AA07
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-VATC |
QD08AJ03
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-VATC |
QB05CA01
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
||
|
WHO-ATC |
B05CA01
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB13306MIG
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
7773-52-6
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
2683
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
3083
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
DB11073
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
2286
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | RxNorm | ||
|
Cetylpyridinium
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
D002594
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
7773-52-6
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
CUB7JI0JV3
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY | |||
|
C83615
Created by
admin on Sat Jun 26 07:30:46 UTC 2021 , Edited by admin on Sat Jun 26 07:30:46 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
